WO2005050202A3 - Biological materials and uses thereof - Google Patents
Biological materials and uses thereof Download PDFInfo
- Publication number
- WO2005050202A3 WO2005050202A3 PCT/GB2004/004781 GB2004004781W WO2005050202A3 WO 2005050202 A3 WO2005050202 A3 WO 2005050202A3 GB 2004004781 W GB2004004781 W GB 2004004781W WO 2005050202 A3 WO2005050202 A3 WO 2005050202A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- smad
- tieg
- test compound
- expression
- providing
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004292012A AU2004292012A1 (en) | 2003-11-18 | 2004-11-12 | Biological materials and uses thereof |
CA002546397A CA2546397A1 (en) | 2003-11-18 | 2004-11-12 | Biological materials and uses thereof |
EP04798502A EP1690098A2 (en) | 2003-11-18 | 2004-11-12 | Biological materials and uses thereof |
JP2006540575A JP2007515161A (en) | 2003-11-18 | 2004-11-12 | Biological substances and their use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0326778.8A GB0326778D0 (en) | 2003-11-18 | 2003-11-18 | Biological materials and uses thereof |
GB0326778.8 | 2003-11-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005050202A2 WO2005050202A2 (en) | 2005-06-02 |
WO2005050202A3 true WO2005050202A3 (en) | 2005-11-03 |
Family
ID=29763970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2004/004781 WO2005050202A2 (en) | 2003-11-18 | 2004-11-12 | Biological materials and uses thereof |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1690098A2 (en) |
JP (1) | JP2007515161A (en) |
CN (1) | CN1906490A (en) |
AU (1) | AU2004292012A1 (en) |
CA (1) | CA2546397A1 (en) |
GB (1) | GB0326778D0 (en) |
WO (1) | WO2005050202A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101877698B1 (en) * | 2008-08-25 | 2018-07-12 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
US8946172B2 (en) | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
MX365647B (en) | 2011-02-02 | 2019-06-10 | Excaliard Pharmaceuticals Inc | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf). |
CN104487574B (en) | 2012-04-18 | 2017-07-07 | 诺格尔制药有限公司 | Treatment diabetes and/or the method for promoting survival after pancreatic islets transplantation |
CN117677692A (en) * | 2021-05-21 | 2024-03-08 | 江苏九济华生医药科技研究院有限公司 | Cell strain for TGF beta detection and high-precision TGF beta detection method |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000035936A1 (en) * | 1998-12-14 | 2000-06-22 | University Of Miami | Connective tissue growth factor fragments and methods and uses thereof |
US6555322B1 (en) * | 1999-08-27 | 2003-04-29 | Fibrogen, Inc. | α2-macroglobulin receptor as a receptor for CTGF |
WO2005050203A2 (en) * | 2003-11-18 | 2005-06-02 | Imperial College Innovations Limited | The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis |
-
2003
- 2003-11-18 GB GBGB0326778.8A patent/GB0326778D0/en not_active Ceased
-
2004
- 2004-11-12 CN CNA2004800406363A patent/CN1906490A/en active Pending
- 2004-11-12 WO PCT/GB2004/004781 patent/WO2005050202A2/en active Application Filing
- 2004-11-12 JP JP2006540575A patent/JP2007515161A/en not_active Withdrawn
- 2004-11-12 CA CA002546397A patent/CA2546397A1/en not_active Abandoned
- 2004-11-12 AU AU2004292012A patent/AU2004292012A1/en not_active Abandoned
- 2004-11-12 EP EP04798502A patent/EP1690098A2/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000035936A1 (en) * | 1998-12-14 | 2000-06-22 | University Of Miami | Connective tissue growth factor fragments and methods and uses thereof |
US6555322B1 (en) * | 1999-08-27 | 2003-04-29 | Fibrogen, Inc. | α2-macroglobulin receptor as a receptor for CTGF |
WO2005050203A2 (en) * | 2003-11-18 | 2005-06-02 | Imperial College Innovations Limited | The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis |
Non-Patent Citations (3)
Title |
---|
ABDEL WAHAB N ET AL: "Modulation of the TGFbeta/Smad signaling pathway in mesangial cells by CTGF/CCN2", EXPERIMENTAL CELL RESEARCH, SAN DIEGO, CA, US, vol. 307, no. 2, 15 July 2005 (2005-07-15), pages 305 - 314, XP004927162, ISSN: 0014-4827 * |
JOHNSEN STEVEN A ET AL: "TGFbeta inducible early gene enhances TGFbeta/Smad-dependent transcriptional responses", ONCOGENE, vol. 21, no. 37, 22 August 2002 (2002-08-22), pages 5783 - 5790, XP002339186, ISSN: 0950-9232 * |
NAKAO ATSUHITO ET AL: "Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice", JOURNAL OF CLINICAL INVESTIGATION, vol. 104, no. 1, July 1999 (1999-07-01), pages 5 - 11, XP002339185, ISSN: 0021-9738 * |
Also Published As
Publication number | Publication date |
---|---|
EP1690098A2 (en) | 2006-08-16 |
CA2546397A1 (en) | 2005-06-02 |
AU2004292012A1 (en) | 2005-06-02 |
JP2007515161A (en) | 2007-06-14 |
CN1906490A (en) | 2007-01-31 |
WO2005050202A2 (en) | 2005-06-02 |
GB0326778D0 (en) | 2003-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006073782A3 (en) | Colorimetric sensors constructed of diacetylene materials | |
WO2008041953A3 (en) | Dengue diagnosis and treatment | |
WO2002027326A3 (en) | Method and kit for the transderaml determination of analyte concentration in blood | |
WO2004091387A3 (en) | Dual measurement analyte detection system | |
WO2007127749A3 (en) | Predicting mortality and detecting severe disease | |
AU1725200A (en) | Simultaneous determination of equilibrium and kinetic properties | |
TW200502550A (en) | Colorimetric sensors constructed of diacetylene materials | |
EP1359417A3 (en) | Devices and methods for analyte concentration determination | |
EP1394541A3 (en) | Ozone gas sensing element, detection apparatus, and measurement method | |
WO2006066274A3 (en) | Breath-based sensors for non-invasive molecular detection | |
SI1776587T1 (en) | Use of c3a and derivatives thereof as biomarker for colorectal adenoma and/or carcinoma ; diagnosis methods and assays using the same | |
WO2003043487A3 (en) | Method of using a non-antibody protein to detect and measure an analyte | |
WO2007079843A3 (en) | Test strip and method for measuring an analyte concentration in a sample of a biological fluid | |
BRPI0507322A (en) | electrochemical biosensor | |
WO2004057314A3 (en) | Polarisation interferometric method and sensor for detecting a chemical substance | |
WO2007059065A3 (en) | Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia | |
WO2004000884A3 (en) | Compositions and methods for apo-b48 and apo-b100 assay | |
WO2007088355A3 (en) | Sepsis test | |
AU2849300A (en) | Methods and assay kits for detecting mononuclear cell phenotype | |
WO2004072606A3 (en) | Polymeric membranes for use in electrochemical sensors | |
WO2007061940A3 (en) | Method for detecting an inflammatory disease or cancer | |
WO2007094805A3 (en) | Method for electrocatalytic protein detection | |
AU2003215467A1 (en) | Method and device for predicting cardiovascular events | |
WO2005050203A3 (en) | The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis | |
WO2005050202A3 (en) | Biological materials and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2546397 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006540575 Country of ref document: JP Ref document number: 547297 Country of ref document: NZ Ref document number: 2821/DELNP/2006 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004292012 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004798502 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004292012 Country of ref document: AU Date of ref document: 20041112 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004292012 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200480040636.3 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004798502 Country of ref document: EP |